Overview of the cellular and molecular basis of kidney fibrosis

Slides:



Advertisements
Similar presentations
Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup
Advertisements

Volume 62, Issue 6, Pages (December 2002)
Reduced renal function in patients with simple renal cysts
Volume 77, Issue 9, Pages (May 2010)
Acute interstitial nephritis
Current status of end-stage renal disease care in India and Pakistan
The Case | Renal failure in a bodybuilder athlete
Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis  Akira Shimizu, Kazuhiko Yamada, David.
Volume 68, Issue 6, Pages (December 2005)
Mark A. Lusco, MD, Agnes B. Fogo, MD, Behzad Najafian, MD, Charles E
Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification 
David J. Nikolic-Paterson, Shuang Wang, Hui Yao Lan 
Volume 74, Issue 10, Pages (November 2008)
Current status of end-stage renal disease care in India and Pakistan
Volume 57, Issue 4, Pages (April 2000)
Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis  Joseph V. Bonventre  Kidney.
Acute interstitial nephritis
Kidney transplantation in a low-resource setting: Nigeria experience
Volume 64, Issue 1, Pages (July 2003)
Macrophage heterogeneity, phenotypes, and roles in renal fibrosis
Figure 6 Schematic of an analysis of a new biopsy
IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy  J.-A. Moon,
Functional evidence confirmed by histological localization: overlapping expression of erythropoietin and HIF-2α in interstitial fibroblasts of the renal.
Volume 70, Issue 7, Pages (October 2006)
Benjamin D. Humphreys  Kidney International Supplements 
EGFR signaling in renal fibrosis
Burden of chronic kidney disease: North Africa
Chapter 3: Management of progression and complications of CKD
Chapter 5: Referral to specialists and models of care
Volume 75, Issue 12, Pages (June 2009)
Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy  Shinya Mizuno, Kunio Matsumoto, Toshikazu Nakamura 
AOPPs and the progression of kidney disease
Volume 86, Issue 4, Pages (October 2014)
Volume 68, Issue 6, Pages (December 2005)
Volume 70, Issue 7, Pages (October 2006)
Volume 70, Issue 11, Pages (December 2006)
The heterogeneous mononuclear phagocyte system of the kidney
Volume 67, Issue 1, Pages (January 2005)
Saulo Klahr, Jeremiah J. Morrissey  Kidney International 
Volume 70, Issue 12, Pages (December 2006)
Macrophages and hypoxia in human chronic kidney disease
Expression of connective tissue growth factor in human renal fibrosis
Volume 72, Issue 2, Pages (July 2007)
Adenosine A2A agonists as therapy for glomerulonephritis
Volume 77, Issue 9, Pages (May 2010)
M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang 
Volume 67, Issue 1, Pages (January 2005)
Methods for guideline development
CD4+ T cells: a potential player in renal fibrosis
Reduced renal function in patients with simple renal cysts
Counteracting progression of renal disease: A look into the future
Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials  Christof Westenfelder, Florian E. Togel 
Why is proteinuria an ominous biomarker of progressive kidney disease?
The treatment of acute interstitial nephritis: More data at last
Volume 68, Issue 3, Pages (September 2005)
Current status of maintenance hemodialysis in Beijing, China
Volume 63, Issue 2, Pages (February 2003)
Volume 80, Issue 10, Pages (November 2011)
Volume 69, Issue 10, Pages (May 2006)
BK virus nephritis after renal transplantation
Charles A. Herzog  Kidney International 
Is complement a target for therapy in renal disease?
Volume 70, Issue 3, Pages (August 2006)
A nest in renal fibrosis?
Volume 58, Issue 3, Pages (September 2000)
The more or less ‘pristine’ renal allograft biopsy
Volume 82, Issue 9, Pages (November 2012)
B cells and tertiary lymphoid organs in renal inflammation
The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?  Richard E. Gilbert, Mark E. Cooper  Kidney.
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Presentation transcript:

Overview of the cellular and molecular basis of kidney fibrosis Allison A. Eddy  Kidney International Supplements  Volume 4, Issue 1, Pages 2-8 (November 2014) DOI: 10.1038/kisup.2014.2 Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 1 Schematic overview of the primary fibrogenic events. The upper figure depicts the key elements of the tubulointerstitium in normal kidneys. The myeloid cell population may be designated as dendritic cells rather than macrophages. The lower panel represents the key changes that are discussed further in this review: de novo appearance of an interstitial population of unique fibroblastic cells that also express alpha smooth muscle actin and are the primary source of the expanded extracellular matrix that leads to destructive interstitial scarring; an interstitial inflammatory response composed of primarily of blood-borne lymphohematopoietic cells (macrophages in particular are key drivers of both fibrosis and tissue repair); and progressive renal parenchymal loss due to interstitial capillary rarefaction and tubular atrophy. Graphs illustrate the statistically significant histopathological indicators of renal survival (free of end-stage kidney disease or serum creatinine doubling) with follow-up (shown in months) in a study of 313 patients with biopsy-confirmed lupus nephritis. The severity scores for (a) interstitial inflammation, (b) tubular atrophy, and (c) interstitial fibrosis were based of the following: 0 (nil), normal; 1+ (mild), <25% of the interstitial area affected; 2+ (moderate), 25–50% of the tubulointerstitial are involved; 3+ (severe), >50% of the interstitial area involved. (The graphs are reproduced with permission from Macmillan Publishers Ltd: Yu F et al. Kidney Int 2010;77:820–829.) Kidney International Supplements 2014 4, 2-8DOI: (10.1038/kisup.2014.2) Copyright © 2014 International Society of Nephrology Terms and Conditions